---
title: "Royalty Pharma plc 2026: Revenue $674.14M, EPS $0.04— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294973389.md"
description: "Royalty Pharma reported Q2 2026 results with revenue rising 16.5% to $674.14M, driven by cystic fibrosis and new royalty acquisitions. However, net income fell 44.4% to $17.88M, and diluted EPS declined to $0.04 due to share-based compensation from internalization. The company deployed $876.7M in H1 2026 for investments."
datetime: "2026-08-05T13:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294973389.md)
  - [en](https://longbridge.com/en/news/294973389.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294973389.md)
generator: "portal-rs"
---

# Royalty Pharma plc 2026: Revenue $674.14M, EPS $0.04— 10-Q Summary

Royalty Pharma plc reported results for the 2026 quarter, with revenue rising to $674.14M from $578.67M a year earlier while net income fell to $17.88M and diluted EPS declined to $0.04— per the company's 10-Q filing.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$674.14M

$578.67M

16.5%

Net income²

$17.88M

$32.18M

(44.4%)

Diluted EPS³

$0.04

$0.07

(42.9%)

*¹ Reported as “Total income and other revenues”. ² Reported as “Net income attributable to Royalty Pharma plc”. ³ Reported as “Diluted earnings per share”.*

**Business Highlights**

-   Revenue growth was driven by the cystic fibrosis franchise, Tremfya and newly acquired Imdelltra royalties; overall income from financial royalty assets rose roughly mid-teens year over year.
-   Channel and mix shifts within the cystic fibrosis portfolio moved more sales toward Alyftrek, which lowered the blended royalty rate despite stable receipts.
-   Brand momentum from launches and approvals — including Imdelltra, Voranigo, Trodelvy, Evrysdi and Tremfya — contributed to royalty increases.
-   Operationally, Royalty Pharma completed internalization in May 2025, transitioned to an employee compensation model and recognized substantial share-based compensation expense.
-   Investment activity included $876.7M deployed in H1 2026 to acquire royalties and support R&D deals such as arrangements with Teva, J&J co-funding and Neurimmune cliramitug.

Original SEC Filing: Royalty Pharma plc \[ RPRX \] - 10-Q - Aug. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md)
- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Royalty Pharma EVP and Chairman of Partnering Christopher Hite sells 100,000 shares for $6 million](https://longbridge.com/en/news/296396564.md)
- [If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/296656460.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)
- [RPRX: Q2 2026 delivered double-digit Royalty Receipts growth and raised full-year guidance](https://longbridge.com/en/news/294957965.md)
- [Royalty Pharma CFO Terrance P. Coyne sells USD 645,248 in common shares](https://longbridge.com/en/news/296146007.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**